2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2018, 62: 655-664. PMID: 30569273, PMCID: PMC6402971, DOI: 10.1007/s00125-018-4786-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedArea Under CurveAutoimmunityC-PeptideCD3 ComplexCD8-Positive T-LymphocytesChildCytokinesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIslets of LangerhansMaleRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeYoung AdultConceptsC-peptide responseType 1 diabetesMixed meal tolerance testDetectable C-peptideC-peptideInsulin useTolerance testT cellsControl groupNew-onset type 1 diabetesPeripheral blood mononuclear cellsConclusions/interpretationThese findingsAnti-CD3 monoclonal antibodyDaily insulin useBlood mononuclear cellsDiagnosis of diabetesSuccessful immune therapiesOriginal control groupCell death proteinAnergic CD8ResultsFifty-sixImmune therapyInterpretationThese findingsMononuclear cellsCytokine release
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisC-peptide levelsCharacteristics of patientsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab
2007
High Visceral and Low Abdominal Subcutaneous Fat Stores in the Obese Adolescent A Determinant of an Adverse Metabolic Phenotype
Taksali SE, Caprio S, Dziura J, Dufour S, Calí A, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R. High Visceral and Low Abdominal Subcutaneous Fat Stores in the Obese Adolescent A Determinant of an Adverse Metabolic Phenotype. Diabetes 2007, 57: 367-371. PMID: 17977954, DOI: 10.2337/db07-0932.Peer-Reviewed Original ResearchConceptsMetabolic syndromeObese adolescentsInsulin resistanceVisceral fatSubcutaneous fatAdverse metabolic phenotypeC-reactive proteinSevere metabolic complicationsAbdominal subcutaneous fatBMI z-scoreProton magnetic resonance spectroscopyMulti-ethnic cohortFat-free massSubcutaneous fat depotsMagnetic resonance imagingSubcutaneous fat storesMetabolic complicationsTotal adiponectinHepatic fatLiver fatTriglyceride levelsInterleukin-6Visceral depotsOdds ratioC-peptide
2004
The Normal Glucose Tolerance Continuum in Obese Youth: Evidence for Impairment in β-Cell Function Independent of Insulin Resistance
Yeckel CW, Taksali SE, Dziura J, Weiss R, Burgert TS, Sherwin RS, Tamborlane WV, Caprio S. The Normal Glucose Tolerance Continuum in Obese Youth: Evidence for Impairment in β-Cell Function Independent of Insulin Resistance. The Journal Of Clinical Endocrinology & Metabolism 2004, 90: 747-754. PMID: 15522932, DOI: 10.1210/jc.2004-1258.Peer-Reviewed Original ResearchConceptsBeta-cell responsivenessNormal glucose tolerancePlasma glucose levelsGlucose levelsGlucose toleranceInsulin sensitivityPlasma glucoseObese youthOral glucose tolerance testType 2 diabetes mellitusDecreased insulinogenic indexGlucose tolerance continuumGlucose tolerance testInsulin sensitivity indexContinuum of riskDelta insulinInsulinogenic indexDiabetes mellitusInsulin resistancePlasma levelsTolerance testNormal rangeFunction IndependentDlGlucose concentration